Gene Therapy
-
Permission granted by Rocket Pharmaceuticals
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.
By Ben Fidler • March 27, 2026 -
Robert Way via Getty Images
China competitionAstraZeneca to boost cell therapy capabilities with new China investment
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.
By Ben Fidler • March 19, 2026 -
Explore the Trendline➔
Getty Images
TrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
Getty Images
News roundupSarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
By Ben Fidler • March 16, 2026 -
Courtesy of UniQure
UniQure leads genetic medicine biotech rally after news of Prasad’s exit
Vinay Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.
By Jacob Bell • March 9, 2026 -
Permission granted by MilliporeSigma
Sponsored by MilliporeSigmaNavigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies
An often overlooked but critically important step along the path from bench to bedside, PPQ often results in delays and potential non-compliance issues without proper planning.
March 9, 2026 -
Getty Images
Gene editingPrime to test FDA flexibility with 2-patient gene editing submission
The planned filing comes amid heightened scrutiny of the FDA’s rare disease stance and a year after Prime deprioritized the program for economic reasons.
By Kristin Jensen • March 4, 2026 -
Getty Images
UniQure falls further on Makary comments
Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure's gene therapy for Huntington's won't get approved.
By Jacob Bell • Feb. 27, 2026 -
Courtesy of Sarepta
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business.
By Ben Fidler • Feb. 26, 2026 -
Permission granted by Gilead Sciences
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.
By Ben Fidler • Feb. 23, 2026 -
Permission granted by Catalent
Sponsored by CatalentAll about cell therapy process characterization
Why process characterization is the key to consistent, safe, and scalable cell therapies.
Feb. 23, 2026 -
Permission granted by Catalent
Sponsored by CatalentSelecting the optimal cell therapy manufacturing platform
Navigating modular vs. integrated platforms—find the best path for your cell therapy program.
Feb. 17, 2026 -
Permission granted by Vertex
Vertex’s CRISPR therapy rebounds in latest earnings
Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.
By Gwendolyn Wu • Feb. 13, 2026 -
Sarah Silbiger via Getty Images
FDA rejects Regenxbio treatment in another blow to gene therapy
The decision comes two weeks after the agency halted testing due to safety concerns and represents the latest regulatory setback for a gene therapy maker.
By Gwendolyn Wu • Feb. 10, 2026 -
Getty Images
Immune resetLilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.
By Jonathan Gardner • Feb. 9, 2026 -
Permission granted by Catalent
Sponsored by CatalentNavigating the complexities of Cell and Gene Therapy supply chains
Turning complex CGT logistics into certainty—keeping therapies moving to patients.
Feb. 9, 2026 -
Getty Images
Gene editingLilly bets on Seamless, delving further into genetic medicine for hearing loss
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.
By Delilah Alvarado • Jan. 28, 2026 -
Getty Images
Regenxbio gene therapy trials suspended by FDA over safety worries
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.
By Kristin Jensen • Jan. 28, 2026 -
Kevin Frayer via Getty Images
China competitionChina’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.
By Ben Fidler • Jan. 26, 2026 -
Jacob Bell/BioPharma Dive
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
By Jonathan Gardner • Jan. 26, 2026 -
Getty Images
Oxford Biomedica confirms takeover talks with biotech investor EQT
Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited take-private bids from EQT that it felt “undervalued” the company and its prospects.
By Kristin Jensen • Jan. 15, 2026 -
Danielle Ternes/BioPharma Dive
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.
By BioPharma Dive staff • Jan. 14, 2026 -
Getty Images
Startup launchesAddition emerges with $100M to make gene therapies for chronic and rare diseases
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes can sidestep issues seen with traditional gene therapy technology.
By Gwendolyn Wu • Dec. 17, 2025 -
Getty Images
Biotech zombies‘Zombie’ biotech buyer Xoma to acquire Generation Bio
The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.
By Gwendolyn Wu • Dec. 16, 2025 -
Permission granted by Kyverna Therapeutics
Immune resetKyverna to seek first clearance of a CAR-T therapy for autoimmune disease
The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition called stiff person syndrome that has no approved therapies.
By Ben Fidler • Dec. 15, 2025 -
Getty Images
Hemophilia gene therapies are struggling on the market, even as innovation soars
The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.
By Kelly Bilodeau • Dec. 5, 2025
